Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,466,488
  • Shares Outstanding, K 2,022,193
  • Annual Sales, $ 45,006 M
  • Annual Income, $ 8,025 M
  • 60-Month Beta 0.38
  • Price/Sales 2.31
  • Price/Cash Flow 4.12
  • Price/Book 3.54
Trade BMY with:

Options Overview Details

View History
  • Implied Volatility 22.66% ( -0.16%)
  • Historical Volatility 18.26%
  • IV Percentile 68%
  • IV Rank 43.74%
  • IV High 30.66% on 01/29/24
  • IV Low 16.43% on 06/16/23
  • Put/Call Vol Ratio 1.44
  • Today's Volume 22,300
  • Volume Avg (30-Day) 35,394
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 587,703
  • Open Int (30-Day) 591,316

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 1.53
  • Number of Estimates 9
  • High Estimate 1.75
  • Low Estimate 1.30
  • Prior Year 2.05
  • Growth Rate Est. (year over year) -25.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.58 +6.18%
on 02/06/24
51.92 -2.70%
on 02/23/24
+0.82 (+1.65%)
since 01/26/24
3-Month
47.58 +6.18%
on 02/06/24
53.48 -5.53%
on 12/22/23
+0.76 (+1.53%)
since 11/24/23
52-Week
47.58 +6.18%
on 02/06/24
71.07 -28.91%
on 04/06/23
-19.66 (-28.01%)
since 02/24/23

Most Recent Stories

More News
Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech...

BMY : 50.52 (-2.21%)
EXEL : 21.96 (+2.00%)
RCUS : 19.66 (+0.67%)
VNDA : 4.56 (+2.47%)
VRTX : 433.48 (+0.78%)
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside

Shares of these companies are trading at sizable earnings discounts.

TPR : 47.62 (-1.92%)
PYPL : 59.33 (+0.29%)
BMY : 50.52 (-2.21%)
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?

Patience will be rewarded with these stocks.

PFE : 27.18 (-2.09%)
BMY : 50.52 (-2.21%)
Pharma Stocks Analysis: Grab, Hold, or Sell?

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers...

BMY : 50.52 (-2.21%)
COLL : 36.56 (+0.58%)
PCVX : 78.97 (+2.73%)
PFE : 27.18 (-2.09%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 0.9900 (+0.31%)
ONC.TO : 1.33 (-1.48%)
TCRX : 6.79 (+0.44%)
BMY : 50.52 (-2.21%)
PDSB : 5.54 (+2.21%)
CCCC : 9.51 (+5.78%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.9900 (+0.31%)
ONC.TO : 1.33 (-1.48%)
EXEL : 21.96 (+2.00%)
PFE : 27.18 (-2.09%)
BTAI : 3.10 (+0.98%)
BMY : 50.52 (-2.21%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

ONCY : 0.9900 (+0.31%)
ONC.TO : 1.33 (-1.48%)
EXEL : 21.96 (+2.00%)
PFE : 27.18 (-2.09%)
BTAI : 3.10 (+0.98%)
BMY : 50.52 (-2.21%)
Elite 4 Biotech Stocks to Buy Now for Explosive Returns

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear...

BMY : 50.52 (-2.21%)
CORT : 23.13 (+3.03%)
EXEL : 21.96 (+2.00%)
INCY : 60.53 (-0.10%)
JAZZ : 132.77 (+0.37%)
MOR : 17.69 (+0.40%)
RCUS : 19.66 (+0.67%)
S&P 500 and Nasdaq 100 Climb to Record Highs on U.S. Economic Optimism

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.03%. Stock...

$SPX : 5,069.53 (-0.38%)
SPY : 505.99 (-0.37%)
$DOWI : 39,069.23 (-0.16%)
DIA : 390.71 (-0.15%)
$IUXX : 17,933.33 (-0.02%)
QQQ : 436.55 (-0.05%)
EMR : 106.19 (+0.26%)
CMG : 2,660.45 (+0.52%)
PANW : 302.78 (+7.33%)
CRWD : 321.03 (+3.06%)
FTNT : 68.40 (+1.12%)
ZS : 241.70 (+2.75%)
Pancreatic Cancer Treatments Poised for Major Advances in 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.9900 (+0.31%)
ONC.TO : 1.33 (-1.48%)
INCY : 60.53 (-0.10%)
TNGX : 11.37 (-1.13%)
BMY : 50.52 (-2.21%)
RYZB : 62.49 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 52.52
2nd Resistance Point 52.10
1st Resistance Point 51.31
Last Price 50.52
1st Support Level 50.10
2nd Support Level 49.68
3rd Support Level 48.89

See More

52-Week High 71.07
Fibonacci 61.8% 62.09
Fibonacci 50% 59.32
Fibonacci 38.2% 56.55
Last Price 50.52
52-Week Low 47.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar